Viatris
Pharma0
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
0
Indications↗
Distinct diseases across all programs
6
Clinical Trials↗
All sponsored trials (all statuses)
Activity
Recent Activity
Last 14 days
Sep 11, 2026
Recruiting
A Phase 4, Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, Six-Way Crossover Study Evaluating the Abuse Potential of Gabapentin Taken Orally Concomitantly With Oxycodone Hydrochloride in Healthy, Non-Drug- Dependent, Recreational Opioid Users
Sep 9, 2026
Completed
A Phase 4, Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, Four-Way Crossover Study Evaluating the Abuse Potential of Two Doses of Gabapentin Taken Orally in Healthy, Non-Drug-Dependent Participants With Sedative Drug Use Experience
Earlier
Aug 18, 2026TrialMulticenter, Phase 4, Single-Arm Clinical Trial to Evaluate Efficacy and Safety of Dymista (Azelastine Hydrochloride and Fluticasone Propionate) Nasal Spray in the Treatment of Allergic Rhinitis in Chinese Adolescents With or Without Ocular Symptoms.
Apr 1, 2024TrialA Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Mar 1, 2024TrialA Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions
Jul 23, 2023TrialSafety and Efficacy Evaluation of <Dovprela Tablets 200 mg> by Post-marketing Surveillance
Regulatory
Regulatory Timeline
20011 event
FDAFeb 16
Foradil — FORADIL
Application NDA020831 (NDA)
20061 event
FDADec 15
Foradil — FORADIL CERTIHALER
Application NDA021592 (NDA)
20071 event
FDAMay 11
Foradil — PERFOROMIST
Application NDA022007 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)